Genetic polymorphisms in the Fas and FasL genes are associated with epithelial ovarian cancer risk and clinical outcomes

Gynecologic Oncology

Volumn 128, Issue 3, 2013, Pages 584-589

  Li, Yan ^a   Hao, Ya Li ^a   Kang, Shan ^a   Zhou, Rong Miao ^a   Wang, Na ^a   Qi, Bing Li ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Clinical outcome; Epithelial ovarian cancer; Fas; FasL; Polymorphisms; Risk

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CARCINOMA; PRIORITY JOURNAL;

ADULT; AGED; ANTIGENS, CD95; CASE-CONTROL STUDIES; FAS LIGAND PROTEIN; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84873731556     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.12.002     Document Type: Article

References (32)

1. M. Zörnig, A. Hueber, W. Baum, and G. Evan Apoptosis regulators and their role in tumorigenesis Biochim Biophys Acta 1551 2001 F1 F37
2. C.B. Thompson Apoptosis in the pathogenesis and treatment of disease Science 267 1995 1456 1462
3. G.I. Evan, and K.H. Vousden Proliferation, cell cycle and apoptosis in cancer Nature 411 2001 342 348
4. S.W. Lowe, and A.W. Lin Apoptosis in cancer Carcinogenesis 21 2000 485 495
5. K.M. Hajra, and J.R. Liu Apoptosome dysfunction in human cancer Apoptosis 9 2004 691 704
6. S. Nagata, and P. Golstein The Fas death factor Science 267 1995 1449 1456
7. A. Oehm, I. Behrmann, W. Falk, M. Pawlita, G. Maier, and C. Klas PH Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor family J Biol Chem 267 1992 10709 10715
8. T. Suda, T. Takahashi, P. Golstein, and S. Nagata Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family Cell 75 1993 1169 1178
9. H. Rabinowich, T.E. Reichert, Y. Kashii, B.R. Gastman, M.C. Bell, and T.L. Whiteside Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes J Clin Invest 101 1998 257 288
10. T. Crnogorac-Jurcevic, E. Efthimiou, P. Capelli, E. Blaveri, A. Baron, and B. Terris Gene expression profiles of pancreatic cancer and stromal desmoplasia Oncogene 20 2001 7437 7446
11. M. Muschen, U. Warskulat, and M.W. Beckmann Defining CD95 as a tumor suppressor gene J Mol Med 78 2000 312 325
12. M. Fraser, B. Leung, A. Jahani-Asl, X. Yan, W.E. Thompson, and B.K. Tsang Chemoresistance in human ovarian cancer: the role of apoptotic regulators Reprod Biol Endocrinol 1 2003 66
13. E.W. Duiker, A.G. van der Zee, P. de Graeff, W. Boersma-van Ek, H. Hollema, and G.H. de Bock The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer Gynecol Oncol 116 2010 549 555
14. P. Chaudhry, R. Srinivasan, and F.D. Patel Expression of the major fas family and Bcl-2 family of proteins in epithelial ovarian cancer (EOC) and their correlation to chemotherapeutic response and outcome Oncol Res 18 2010 549 559
15. Q.R. Huang, D. Morris, and N. Manolios Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene Mol Immunol 34 1997 577 582
16. J. Wu, C. Metz, X. Xu, R. Abe, A.W. Gibson, and J.C. Edberg A novel polymorphic CAAT/enhancerbinding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients J Immunol 170 2003 132 138
17. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer 47 1981 207 214
18. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
19. S.A. Miller, D.D. Dybes, and H.F. Polesky A simple salting out procedure for extracting DNA from human nucleated cells Nucleic Acid Res 16 1988 1215
20. W. Zhang, C. Li, J. Wang, and C. He Functional polymorphisms in FAS/FASL system contribute to the risk of occurrence but not progression of gastric cardiac adenocarcinoma Hepatogastroenterology 59 2012 141 146
21. L.X. Qiu, J. Shi, H. Yuan, X. Jiang, K. Xue, and H.F. Pan FAS - 1,377 G/A polymorphism is associated with cancer susceptibility: evidence from 10,564 cases and 12,075 controls Hum Genet 125 2009 431 435
22. Z. Zhang, H. Xue, W. Gong, M. Wang, L. Yuan, and S. Han FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies Carcinogenesis 30 2009 487 493
23. Z. Zhang, L. Qiu, M. Wang, N. Tong, J. Li, and Z. Zhang The FAS ligand promoter polymorphism, rs763110 (- 844C>T), contributes to cancer susceptibility: evidence from 19 case-control studies Eur J Hum Genet 17 2009 1294 1303
24. U. Gormus, A. Ergen, H. Yilmaz, B. Dalan, S. Berkman, and T. Isbir Fas-1377A/G and FasL-844 T/C gene polymorphisms and epithelial ovarian cancer Anticancer Res 27 2007 991 994
25. B. Zhang, T. Sun, L. Xue, X. Han, B. Zhang, and N. Lu Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer Carcinogenesis 28 2007 1067 1073
26. N.J. Sunter, K. Scott, R. Hills, D. Grimwade, S. Taylor, and L.J. Worrillow A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia Blood 119 2012 196 205
27. G. Knechtel, G. Hofmann, A. Gerger, W. Renner, T. Langsenlehner, and J. Szkandera Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer J Cancer Res Clin Oncol 136 2010 1813 1819
28. G. Hofmann, U. Langsenlehner, T. Langsenlehner, B. Yazdani-Biuki, H. Clar, and A. Gerger A common hereditary single-nucleotide polymorphism in the gene of FAS and colorectal cancer survival J Cell Mol Med 13 2009 3699 3702
29. J.Y. Park, W.K. Lee, D.K. Jung, J.E. Choi, T.I. Park, and E.B. Lee Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer Clin Cancer Res 15 2009 1794 1800
30. L.J. Havrilesky, A. Elbebdary, J.A. Hurteau, R.S. Whitaker, G.C. Rodriguez, and A. Berchuck Chemotherapy-induced apoptosis in epithelial ovarian cancer Obstet Gynecol 85 1995 1007 1010
31. D.A. Anthoney, A.J. McIlwrath, W.M. Gallagher, A.R. Edlin, and R. Brown Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells Cancer Res 56 1996 1374 1387
32. P. Chaudhry, R. Srinivasan, F.D. Patel, S. Gopalan, and S. Majumdar Serum soluble Fas levels and prediction of response to platinum-based chemotherapy in epithelial ovarian cancer Int J Cancer 122 2008 1716 1721